Quest Diagnostics has launched its OVA1 ovarian cancer blood test in the US. The diagnostic, which the firm developed with Vermillion, is designed to determine whether a pelvic mass is malignant or benign. Test results should help direct patients to the most appropriate surgeon to ...
Please Login to read the full article.
